| 100 Hue test, 252 | assessment, 417-18 | assessment, 93-4 |
|--|--|---|
| ABC model of anosognosia, 166 | fatigue impact, 381 | causative strokes, 90–1, 93 |
| abnormal involuntary movement, 43 classification, 43 | standardized observation, 59 training, 60 | MCA lesions, 92–3 PCA lesions, 91–2 |
| permanent movement disorders, 46 dystonia, 46–8 tremor, 48–50 vascular generalized chorea, 52 vascular parkinsonism, 50–2 transient movement disorders, 43 asterixis, 45–6 | acute confusional state (ACS), 315, 340 characteristics, 340–1 differential diagnosis, 342 management, 346–7 pathophysiology, 341–2 see also delirium aggressive behavior, 358–9 | clinical presentation, 89 management, 95 prognosis, 94–5 with agraphia, 87 with anomia, 88–9 without agraphia, 87 see also dyslexia |
| episodic paroxysmal dyskinesia, | agnosia, 35, 247 | Alice in Wonderland syndrome, 181 |
| 46 hemiballism-hemichorea, 43-5 | apperceptive, 214, 247, 248 | alien hand phenomenon, 33, 37 |
| see also specific conditions | form agnosia, 248 integrative agnosia, 248 | allocentric neglect, 87 |
| abulia, 335 abulia major, <i>see</i> akinetic mutism abulia minor, 337 | associative, 247, 248–50 from disconnection, 249 from loss of semantic knowledge, | alteration of level of consciousness, 312–13 acute conditions, 315–17 evaluation, 312–13 |
| acalculia, 23, 101 assessment, 110 dissociating numbers and language, 108–9 | 249–50 auditory, 114, 118–19, 120 object, 248–50 visual, 247 | frequency, 320 mechanisms, 318–20 prognostic significance, 320 stroke syndrome associations, |
| Gerstmann syndrome, 109–10 mental calculation deficits, 106–8 approximate vs. exact calculation, 107–8 conceptual processing, 108 | assessment, 251–3 causes, 250 color, 250 management, 253 prognosis, 253 | 320–30 anterior cerebral artery lesions, 330 MCA lesions, 330 midbrain lesions, 321–3, 327–9 |
| elementary calculation, 107 executive control and sequencing, 107 | strokes and, 250–1 agraphia, 86, 89, 90 assessment, 93–4 | pontine lesions, 327–9 rostral basilar artery occlusion, 320–1 |
| input/output processes, 106 spatial layout of arithmetic | causative strokes, 90–1, 93 MCA lesions, 92–3 | thalamic lesions, 321–3, 324–7 subacute/chronic conditions, 317 |
| problems, 106–7 number-transcoding deficits, 105 | clinical presentation, 89 management, 95 | alternating motion rate, 79 |
| quantity-processing deficits, 105–6 core semantic deficits, 105–6 | prognosis, 94–5 with alexia, 87 | Alzheimer disease, 3–4, 397 treatment, 427 |
| neglect and the number line, 106, 145 numerosity perception, 106 | akinetic mutism, 23, 25–6, 38, 317, 334, 335 associated strokes, 336–7 | Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog): 417 |
| rehabilitation, 110 spatial acalculia, 104 | causes, 336 differential diagnosis, 335–6 | amnesia, 24, 38 |
| achromatopsia, 39, 234, 250 | fronto-diencephalic form, 334 | assessment, 287 management, 288–9 |
| activation regulation function assessment, 267 | management, 337 thalamic form, 334 | prognosis and recovery, 288 thalamic lesions and, 36 |
| activities of daily living | Albert Test, 144 alexia, 23, 35, 86, 90 | see also episodic memory; memory disturbances |

| amusia, 114, 119-20 | apallic syndrome, see persistent | arousal, 313 |
|---|---|--|
| β-amyloid (Aβ), 4, 397 amyloid angiopathy, 2, 12 | vegetative state apathy, 38, 256-7, 358 | ascending reticular activating system (ARAS), 313–15 |
| amyloid precursor protein, 4, 397 | CADASIL and, 394 | asomatognosia, 170-1 |
| | Apathy Evaluation Scale, 417 | assessment, 183–5 |
| anarthric tetraparesis, 336 | aphasia, 23, 65, 284-5 | documentation, 184 hemiasomatognosia, 171–3 |
| anomia, with alexia, 88-9 | aphasic syndromes, 65–6, 68–9 | phantom limbs, 173–6 |
| anomic aphasia, 35, 67 | crossed aphasia, 69 mixed transcortical aphasia, 68 | supernumerary, 174–6 |
| anosodiaphoria, 38 | subcortical aphasia, 69 | rehabilitation, 185 |
| anosognosia, 35, 38, 127, 158, 172–3 | assessment, 71–2 | Assessment of Intelligibility in |
| anatomical correlates, 142 | imaging techniques, 70-1 | Dysarthric Speakers, 78 |
| as prognostic marker, 162-3 | oral comprehension, 65 | Association Internationale Polar la |
| assessment, 163–4 | oral production, 65 | Recherche et "Enseignement en |
| causative strokes, 161–2 | causative stroke, 69–70, 284–5 MCA infarct association, 35, 69 | Neurosciences" (AIREN), see |
| clinical features, 158–9 degree of severity, 159 | characteristics, 69 | NINDS-AIREN |
| for blindness, 209 | fluent, 35, 67-8 | associative agnosia, 247, 248-50 |
| incidence after stroke, 159–61 | anomic aphasia, 67 | from disconnection, 249 |
| pathogenesis, 164-6 | conduction aphasia, 68 | from loss of semantic knowledge, 249-50 |
| ABC model, 166 | transcortical sensory aphasia, 68 | |
| concomitant disorders, 164 disconnection mechanism, 165 | Wernicke aphasia, 67–8 mimicking conditions, 71 | associative prosopagnosia, 236 |
| discovery theory, 165 | non-fluent, 66–7, 336 | asterixis, 45-6 |
| feedforward theory, 165–6 | Broca aphasia, 67 | asymmetry, see functional asymmetry |
| motor awareness theory, 166 | global aphasia, 66 | ataxic dysarthria, 80–1 |
| psychological motivation, 165 | transcortical motor aphasia, 67 optic, 35, 247, 249 | athymormia, 334 |
| two-factor theory, 166 unilateral neglect relationship, | prognosis, 72 | associated strokes, 337 |
| 164–5 | treatment, 72–3 | see also akinetic mutism |
| recovery, 162 | pharmacotherapy, 73 | attention, 297, 302 |
| therapy, 166–7 | speech and language therapy, | dorsal attention network, 302 |
| Anosognosia for Hemiplegia | 72–3 transcranial magnetic | ventral attention network, 302 |
| Questionnaire, 163 | stimulation, 73 | attention disorders, 258 |
| anterior cerebral artery, lesions | aphasic mutism, 23 | attentional process assessment, 267 |
| alteration of level of consciousness, 330 | apperceptive agnosia, 214, 247, | audiometry, see auditory perception |
| delirium and, 344–5 | 248 | disorders; deafness |
| dysexecutive syndrome, 263 | form agnosia, 248 | auditory agnosia, 114, 118–19, 120 |
| hemineglect association, 138 | integrative agnosia, 248 | auditory neglect, 120 |
| left, 33–5 right, 37 | apperceptive prosopagnosia, 236 | auditory perception disorders, 114, 116 |
| anterior choroidal artery, lesions | Apple test, 145 | anatomical correlations, 115–16, 120 |
| left, 35 | apraxia, 23, 285 | audiometric assessment, 121–2 |
| right, 37 | assessment, 57 | dichotic listening test, 122 evoked auditory potentials, 122 |
| anterior communicating artery | gestural impairment, 58–9 | oto-acoustic emissions, 122 |
| aneurysm, 264–5, 282–3, 337 | object/tool use impairment, 59 classification, 56–7 | sequences of auditory signals, 122 |
| antidepressant therapy, 367–9 | constructional, see | standard pure tone audiometry, 121 |
| antihypertensive therapy, 424–5, 426–7 | visuoconstructive disorders | word discrimination test, 121 |
| antipsychotic therapy, 353 | functional implications, 59–60 | see also deafness |
| 17 | limb apraxia, 55 neural basis, 61 | auditory hallucinations, 121 |
| antithrombotics, recurrent stroke prevention, 424 | of speech, 35 | brainstem lesions and, 120–1 |
| = | prognosis and recovery, 60 | causative strokes, 116 |
| Anton syndrome, 39, 209 | treatment, 60–1 | delayed disorders, 115 |
| anxiety, fatigue association, 377 | apraxia screen of TULIA, 58-9 | diagnostic circumstances, 114–15 |

| au ditamu hallu simati ama (aaut) |
|---|
| auditory hallucinations (<i>cont</i> .) neuropsychological assessment, 122–3 |
| auditory lexical decision tasks, 123 |
| linguistic and speech perception tests, 122–3 |
| non-speech sounds, 123 phonemic identification and |
| discrimination, 123 |
| receptive musical ability, 123 semantic access and processing, |
| 123 |
| prognosis, 123 transient disorders, 115 |
| treatments, 123–4 |
| autoscopic phenomena, 182-3 |
| Babinski-Nageotte syndrome, 318 |
| Baking Tray task, 145 |
| Bálint syndrome, 24, 39, 218–19, 302–3 assessment, 214, 225–7 |
| associated deficits, 221–2 causes, 224 |
| complete, 219 |
| differential diagnosis, 224 |
| gaze apraxia, 220 |
| in stroke, 224–5 lesion locations, 222–4 |
| minor forms of, 222 |
| numerosity perception deficit, 106 |
| optic ataxia, 219–20 |
| prognosis, 227 rehabilitation strategies, 227 |
| simultanagnosia, 220–1 |
| ballism, 44 see also hemiballism-hemichorea |
| Barthel Index, 417 |
| basal forebrain lesions, memory impairment, 282–3 |
| basic activities in daily living, see activities of daily living |
| basilar artery occlusion, 320–1, 329 |
| Beck Depression Inventory (BDI), 364 |
| Behavioral Dyscontrol Scale, 267 |
| Behavioral Inattention Test, 143 |
| Behavioural Assessment of the |
| Dysexecutive Syndrome, 267 |
| bell cancellation test, 144 |
| Benton Face Recognition Test, 236, 241 |
| bilateral anterior opercular syndrome, 39 |
| bilateral deafness, 23 |

| bilateral lesions, 38-9 |
|--|
| Binswanger disease, 392-3 |
| bipolar disorder, 354 structural brain abnormalities, 355 <i>see also</i> depression; mania |
| Birmingham Object Recognition Battery (BORB), 240, 252 |
| blindness differential diagnosis, 214 psychogenic, 213 see also cortical blindness; specific conditions |
| blindsight, 210 |
| Block-Tapping Task, 205 |
| bodily self, 170–1 image, splitting of <i>see also</i> asomatognosia |
| body disorders, 180 see also specific disorders |
| Boston Diagnostic Aphasia Examination, 65, 71, 416 |
| Boston Naming Test, 415 |
| brain atrophy, 3 fatigue and, 378–9 |
| brainstem evoked auditory potentials, 122 |
| brainstem lesions hearing disorders and, 120–1 |
| Brief Visual Memory Test, Revised, 415 |
| Brixton Test, 258 |
| Broca aphasia, 67 |
| Broca's area working memory and, 301 written language disorders and, 93 |
| CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), 2, 12, 393–6, 400–1 clinical features, 4 |
| white matter abnormalities, 394–6 |
| calcarine artery occlusion, 212 |
| calculation, 102 see also acalculia; number processing |
| California Verbal Learning Test (CVLT), 415 |
| caloric vestibular stimulation, 147, 166, 185 |
| Cambridge Face Memory Test, 241 |

| Canadian Stroke Newton (CSN), see NINDS-CSN |
|--|
| cancellation tasks, 144-5 |
| Capgras syndrome, 37, 352, 353 |
| capsular genu lesion, vascular dementia and, 392 |
| CARASIL (cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy), 396 |
| catastrophic reaction, 36 |
| Catherine Bergego Scale, 164 |
| caudate nucleus lesions delirium and, 345 vascular dementia and, 392 |
| CELEB test, 241 |
| Center for Epidemiologic Study, Depression Scale (CES-D), 416 |
| central executive, 298 deficits, 303-5 |
| central rostrocaudal deterioration syndrome, 318–20 |
| centromedian nucleus lesions, 48 |
| cerebellar tremor, 48–9 |
| cerebral amyloid angiopathy, see amyloid angiopathy |
| cerebral hemorrhage, 265 vascular dementia and, 397–8 |
| cerebral microbleeds, 3 |
| cerebral venous thrombosis, 265 |
| Chicago Multiscale Depression Inventory, 416 |
| cholesterol-lowering therapy, 425 |
| cholinergic deficiency, delirium and, 342 |
| cholinesterase inhibitors Alzheimer disease treatment, 427 CADASIL treatment, 12 delirium treatment, 347 vascular dementia treatment, 402–3, 427–8 |
| chorea, 44 vascular generalized chorea, 52 see also hemiballism-hemichorea |
| clock drawing test, 198, 199 |
| Cloninger Temperament and |
| Character Inventory, 359 |
| Cognitive and Graded Activity Training trial, 383 |
| |
| |

| cognitive behavioral therapy | continuous positive airway pressure, | Delirium Assessment Scale, 343 |
|--|---|---|
| depression, 369 | 383 | Delirium Index, 343 |
| fatigue treatment, 383 | convergence disorders, 321 | Delirium Rating Scale, 343 |
| cognitive impairment, 22 acute focal cognitive deficits, | corpus callosum | Delirium Symptom Interview, 343 |
| 22-6 | lesions, 33–5, 104 | delusion, 38, 351 |
| central visual disturbances, 24 | number-processing role, 103, 104 | assessment, 353 |
| dysexecutive syndrome, 25-6 | Corsi Block Tapping Test, 307 | causative strokes, 352 |
| language disorders, 22–3 | cortical blindness, 24, 39, 209 | frequency in stroke patients, 352 |
| memory disturbances, 24–5 right hemisphere syndrome, 24 | assessment, 213–15 | misidentification delusion, 352–3 treatment, 353, 354 |
| cerebrovascular disease and, 2–4 | electroencephalography, 215 visual evoked potentials, 215 | |
| diagnosis, 28 | causes, 210 | dementia |
| diffuse cognitive disturbances, | clinical symptoms, 209 | CADASIL and, 394 cerebrovascular disease and, 2 |
| 26-8 | management, 215 | pre-stroke dementia detection, 29 |
| mixed pathology, 3–4 post-stroke impairment detection, | prognosis, 211–12 | see also cognitive impairment; |
| 29 | recovery, 212 residual vision, 209–10 | vascular dementia |
| see also vascular cognitive | stroke-related, 211 | demonic possession, 181 |
| impairment | causative strokes, 212-13 | depersonalization, 180-1 |
| cognitive strategy training, 60 | cortical deafness, 23, 114, 116-17, 120 | depression, 36 |
| Collier's sign, 321 | Cotard syndrome, 181, 182, 352 | assessment, 416–17 |
| color agnosia, 250 | C-reactive protein, 379 | fatigue association, 377 frequency in stroke patients, 366 |
| color perception, 214 | crossed aphasia, 69 | future directions, 370 |
| assessment, 252 | | impact after stroke, 367 |
| color recognition disturbances, 250 | deafness | management |
| achromatopsia, 250 | bilateral, 23 cortical, 23, 114, 116–17, 120 | electroconvulsive therapy, 370 pharmacotherapy, 367–9 |
| color agnosia, 250 | pure word, 114, 117–18, 120 | psychological therapies, 369–70 |
| coma, 313, 317, 335 | subtypes, 118 | personality change relationship, 35 |
| somnolent, 321 vigilant, 321 | see also auditory perception | routine screening in stroke patients |
| see also alteration of level of | disorders | 365-6 |
| consciousness; Glasgow Coma | Déjerine syndrome, 318 | symptoms, 364–5 natural history, 366 |
| Scale | delayed-response tests, 259 | vascular depression, 366–7 |
| Composite International Diagnostic | delirium, 26, 315, 340 | diabetes mellitus, 4 |
| Interview (CIDI), 364 | assessment, 342–3 | fatigue and, 377 |
| conceptual apraxia, 57 | causative strokes, 344-6 | management, 425-6 |
| see also apraxia | anterior cerebral artery infarcts, 344–5 | recurrent stroke prevention, 423 |
| conduction aphasia, 35, 68 | head of the caudate nucleus, 345 | Diagnostic and Statistical Manual of |
| confabulations, 25, 282, 283 | inferior genu of the interior | Mental Disorders (DSM), 10, 340, 351, 363, 388-9 |
| configural face processing, 236 | capsule, 345 MCA infarcts, 38, 345 | dichotic listening test, 122 |
| configuration, 236 | PCA infarcts, 344 | digit span test, 307 |
| confusion, <i>see</i> acute confusional state; delirium | subarachnoid hemorrhage, 345–6 thalamic stroke, 344 | Digit Symbol Substitution Test, 414 |
| | characteristics, 340–1 | directional hypokinesia, 130 |
| Confusion Assessment Method, 342 | diagnostic criteria, 340, 341 | disconnection syndromes, 33–5 |
| Confusional State Evaluation, 343 | differential diagnosis, 340–1 incidence in stroke, 344 | anosognosia, 165 |
| clouding of, 315 | management, 346-7 | discovery theory of anosognosia, 165 |
| see also alteration of level of | natural history in stroke, 344 | disengagement deficit, 146 |
| consciousness | prognostic significance, 346 risk factors in stroke patients, 346 | disinhibition, 256 |
| constructional apraxia, see | subtypes, 340 | disintegration syndrome, 35 |
| visuoconstructive disorders | see also acute confusional state | disorientation, 26 |
| | | 410011C11tut1011, 20 |

| divided attention deficit, 259 | sus |
|--|---------------|
| dopamine 1 receptor stimulation, | 300 wo |
| Doppelgänger, 183 | |
| dorsal attention network, 302 | dysgr: sur |
| double homonymous hemianopia | ı, 211 dysgr |
| double monocular elevator palsy, | |
| double simultaneous stimulation, extinction on, 144 | dyslex |
| drawing tasks, 145 visuoconstructive disorder, 193 | |
| DSM, see Diagnostic and Statistico Manual of Mental Disorde | |
| dysarthria, 22, 35, 76, 77 | |
| associated stroke types, 82 ataxic dysarthria, 80–1 | dyslip see |
| classification, 77-8 | dysto |
| evaluation, 78 | mio |
| flaccid dysarthria, 81 | my stri |
| spastic dysarthria, 79 treatments, 82 | tha |
| unilateral upper motor neuron | |
| dysarthria, 79–80 | electr |
| dysexecutive syndrome, 25-6, 38, | 255 |
| assessment, 266–8 | Ekboı |
| bedside assessment, 266 behavioral disturbances, 266 | electr |
| executive cognitive function | |
| optional assessments, 267-8 | emoti |
| behavioral dysexecutive syndro | ome, emoti |
| 255–7, 266–7 characteristics, 260 | enviro |
| cognitive dysexecutive syndron 257, 258, 267 | ne, enviro |
| divided attention and task coordination, 259 | episoo |
| episodic memory impairment, | episoo |
| 259–60 | ass |
| impact on daily life, 261 | im |
| information generation deficit, | C |
| 258-9 | r |
| management, 268–9 | • |
| cognitive rehabilitation, 268- compensatory approach, 269 | |
| pharmacological treatment, response initiation and suppres | 268 |
| 257-8 | 1 |
| response slowing, 260 | 1 |
| rule use and problem-solving deficits, 258 | 1 |
| stroke and, 260–5 | r |
| determinants, 261 | stro |
| lacunar infarct, 264 | t f |
| prevalence, 260-1 | |
| subarachnoid hemorrhage, 2 | 264–5 r |
| territorial infarct, 262-4 | - |

```
tained attention deficit, 259
rking memory, 259
also executive function
aphia
face, 88
aphia, surface, 87
nesia, episodic paroxysmal, 46
ociated lesions, 91
ep, 88
lect, 87
onological, 88
face, 87, 88
also alexia
oidemia management, 427
also hypercholesterolemia
nia, 46-8
dbrain lesions, 48
oclonic, 47
iato-pallidal lesions, 46-7
lamic lesions, 47-8
oencephalography, cortical
  blindness, 215
m syndrome, 181-2
oconvulsive therapy, depression,
  370
ional disturbances, 256
ional incontinence, 38, 358
onmental agnosia, 37
onmental dependency syndrome,
  256, 257
dic buffer, 298
dic memory, 277-8
essment, 205-6, 287
pairment, 24-5
dysexecutive syndrome, 259-60
nanagement, 288-9
prognosis and recovery, 288
vascular dementia, 398-9
okes affecting executive systems,
okes affecting memory-
  processing systems, 284-6
anguage dominant hemispheric
  lesions, 284-5
eft hemispheric lesions, 285
right hemispheric lesions, 285-6
okes causing amnesia, 278-84
pasal forebrain lesions, 282-3
fornix lesions, 280
medial temporal damage, 278-80
etrosplenial cortex lesions, 284
thalamic lesions, 280-2
```

```
episodic paroxysmal dyskinesia, 46
error analysis, 251
evoked auditory potentials, 122
  of brainstem, 122
  of late latency (cortical), 122
  of middle latency (semi-early),
       122
executive function, 255
  CADASIL and, 394
  vascular dementia effects, 398
  see also dysexecutive syndrome
  fatigue management, 383
  fatigue relationship, 378
explicit memory, 277
extinction
  on double simultaneous stimulation,
       144
  perceptual, 129-30
    anatomical correlates, 141-2
eye movement disorders, 214, 220
  assessment, 226
  see also gaze apraxia
Eysenck Personality Inventory, 359
face inversion effect, 237
face recognition, 231
see also prosopagnosia
familiarity, sense of, 352
fatigue, 375
  after stroke, 375, 376, 379
    diagnosis, 380, 381
    epidemiology, 376
    severity assessment, 380-1
  after subarachnoid hemorrhage, 382
    correlated factors, 382
    epidemiology, 382
  associated factors, 376-9
    anxiety, 377
    depression, 377
    neurological impairment, 377
    neurotransmitter/neuro
       endocrine changes, 379
    physical fitness, 378
    pre-stroke fatigue, 377
    sleep disturbance, 378
    sociodemographic factors, 377
    somatic comorbidities, 377
    stroke subtype, 378
    systemic inflammation, 379
    white matter changes/brain
       atrophy, 378-9
  central fatigue, 376
  classification, 379-80
```

| activity-dependent fatigability, | gestures, 55–6 | distinct neglect components, |
|---|--|--|
| 380 | apraxia impact on gestural | 140-2 |
| primary fatigue, 379 secondary fatigue, 379–80 | communication, 59–60 gestural impairment assessment, | egocentric vs. allocentric neglect, 140–1 |
| impact on patients, 382 | 58–9 | near vs. far space neglect, 141 |
| activities of daily living, 381 | gestural training, 60 | role of distributed brain networks, |
| institutionalization, 381 | Glasgow Coma Scale, 313, 317 | 138–40 |
| patients' perception, 381 | global aphasia, 66 | anosognosia relationship, 164–5 |
| quality of life, 381 return to work, 381 | global hyperactivity, 256 | assessment, 143–6 causative strokes, 136 |
| peripheral fatigue, 376 | | characteristics, 134 |
| post-stroke case definition, 380 | global hypoactivity, 256 | clinical manifestations, 126-8 |
| community patients, 380 | glucocorticoid hormones, 341-2 | dissociations between neglect |
| hospital patients, 380 treatment, 382–3 | Goal Management Therapy, 269 | subtypes, 133–4 frames of reference, 131 |
| | GREFEX study, 260, 261 | imaginal representation, 133 |
| feeling of a presence, 183 | Grober and Buschke Test, 394 | implicit processing, 134 |
| fitness, fatigue relationship, 378 | Groupe d'Etude sur la Réeducation et | motor deficits, 130-1 |
| Five Minute Protocol, 414 | l'Evaluation de la Négligence, | perceptual deficits, 128–30 |
| flaccid dysarthria, 81 | 143 | functional neurophysiological anomalies, 143 |
| fluent aphasia, 35, 36, 67-8 | | occurrence in stroke, 135–6 |
| see also aphasia | Hachinski Ischemic Score, 389, 390 | prognosis, 147 |
| Foix-Chavany-Marie syndrome, 39 | hallucinations, 26, 38 | sectors of space, 132-3 |
| foreign accent syndrome, 35 | auditory, 121 | extrapersonal space, 132 peri-personal space, 132 |
| form agnosia, 248 | autoscopic, 182 in cortical blindness, 209 | personal space, 132 |
| Č | kinesthetic, 174 | therapeutic approaches, 147–8 |
| fornix lesions, memory impairment, 280 | Halstead-Reitan Neuropsychological | see also neglect |
| | Battery, 412 | hemiplegia, unawareness of, see |
| Fregoli syndrome, 352 | Hamilton Depression Rating Scale, 364 | anosognosia |
| Frontal Behavioral Inventory, 267, 401 | health-related quality of life, 367 | hereditary cerebral hemorrhages with |
| frontal lesions memory impairment, 286–7 | hearing disorders, see auditory | amyloidosis of Dutch type, 397 |
| see also dysexecutive syndrome | perception disorders; deafness | hereditary cystatin C amyloid angiopathy, 397 |
| Frontal Systems Behavior Scale, 417 | heautoscopy, 182 | herniation |
| frontoparietal control system, 303 | hemianacousia, 117, 122 | central (transtentorial) downward, |
| Frontotemporal Behavioral scale, 401 | hemianopia, 128-9, 211-12 | 318–19, 320 |
| Full Outline of UnResponsiveness | double homonymous, 211 | central (transtentorial) upward, |
| (FOUR) score, 313, 317 | see also cortical blindness | 320 cingulate, 320 |
| functional asymmetry, 32–3 | hemiasomatognosia, 171–3 | lateral (uncal), 318 |
| development, 33 | hemiballism-hemichorea, 43-5 | herpes simplex encephalitis, 71 |
| left hemisphere syndromes, 33-6 | associated lesions, 44 | holistic face processing, 236 |
| right hemisphere syndromes, 34, | causes, 44 mechanisms, 44–5 | assessment, 236–7 |
| 36–8 functional independence measure, 417 | hemichorea, see hemiballism- | Holmes tremor, 48, 49 |
| • | hemichorea | Hopkins Verbal Learning Test (HVLT), |
| fusiform face area, 233, 301 | hemiconcern, 178, 179 | 415 |
| Gage, Phineas, 357 | acute, 37 | horizontal segment of the intraparietal |
| galvanic vestibular stimulation, 147 | hemi-depersonalization, 172 | sulcus, 103 |
| gaze apraxia, 220 | hemineglect, 24, 36–7, 87, 126 | Horner syndrome, 324–5 |
| gaze paresis, 321 | anatomical correlates, 136–7 | hyperactivity, global, 256 |
| generalized anxiety disorder, 38 | cerebrovascular topographic associations, 137–8 | hypercholesterolemia, 423 |
| Gerstmann syndrome, 23, 109–10 | chronic spatial neglect, 142 | management, 425 |
| ,,,,,,,,,,, | | |

Index

| hyperhomocysteinemia, 423-4 | Inventory of Behavioral Dysexecutive | macrosomatognosia, 172 |
|---|---|---|
| management, 426 | Syndrome, 267 | magnetic misreaching, 219 |
| hyperlipidemia, 4 | Iowa Gambling Test, 414 | major hemispheric syndromes, 399 |
| hypersomnia, 317, 321 | jargon aphasia, 35 | malignant hypertensive |
| hypertension, 4 | Judgment of Line Orientation, | encephalopathy, 213 |
| fatigue association, 377 management, 424–5, 426–7 | 416 | mammillothalamic tract, 282 |
| recurrent stroke prevention, | 1. 1.11.1 | mania, 38, 354 |
| 423 | kinesthetic hallucinations, 174 | assessment, 356 |
| hypoactivity, global, 256 | Kocher-Cushing signs, 320 | associated lesions, 356 management, 356 |
| TOD 10 I I I I I I I I I I I I I I I I I I | Koro syndrome, 182 | post-stroke mania, 355 |
| ICD-10, see International Statistical Classification of Diseases and | lacunar infarct deservacutive | associated lesions, 355-6 |
| Related Health Problems, 10th | lacunar infarct, dysexecutive syndrome, 264 | primary versus secondary mania, |
| revision | Landmark Task, 145 | 354 treatment, 356 |
| ideational apraxia, 57 | | see also bipolar disorder |
| see also apraxia | language dissociating numbers and language, | matching tests, 252 |
| ideomotor apraxia, 57 | 108–9 | maze tests, 206 |
| see also apraxia | linguistic perception tests, 122-3 | , |
| illusion des sosies, 352 | tests, 415–16 | MCA, see middle cerebral artery |
| illusionary movements, 174 | language disorders, 22–3 | medial frontal lobe lesions, 33 |
| imaging studies, 4-5 | written language impairment, 23 see also specific disorders | medulla oblongata lesions, 318 |
| aphasia, 70-1 | 1 7 | memantine, 403 |
| vascular cognitive impairment | language therapy see speech and language therapy | Alzheimer disease treatment, 427 vascular dementia treatment, |
| diagnosis, 16 | large vessel disease, 11 | 427–8 |
| imitation, 55 | • | Memorial Delirium Assessment Scale, |
| implicit memory, 277 | lateralization, see functional asymmetry | 343 |
| implicit processing, in spatial neglect, | lateralized disorders of bodily | memory, 277 |
| 134 | consciousness, 172 | assessment, 287, 415 |
| infarcts silent, 2 | Lausanne Emotion in Acute Stroke | explicit, 277 implicit, 277 |
| subcortical, 2 | Study, 260 | semantic, 277 |
| inferior occipital gyrus, face | left hemisphere syndromes, 33-6 | see also episodic memory; memory |
| recognition role, 233 | cognitive syndromes, 33-6 | disturbances; working memory |
| inflammation, fatigue and, 379 | neuropsychiatric syndromes, 36 | memory disturbances, 24-5, 277-8, |
| Informant Questionnaire on Cognitive | letter cancellation test, 144 | 284 CADASH 204 |
| Decline in the Elderly, 29 | leukoaraiosis, 2-3, 11 | CADASIL, 394 episodic memory, 24–5 |
| information generation deficit, 258–9 | limb kinetic apraxia, 57 | assessment, 205-6, 287 |
| instrumental activities of daily living, | see also apraxia | dysexecutive syndrome, 259-60 |
| see activities of daily living | limb praxis, 55-6 | strokes affecting executive systems, 286–7 |
| Instrumental Activities of Daily Living | limb shaking phenomenon, see | strokes affecting memory- |
| Scale, 29 | episodic paroxysmal dyskinesia | processing systems, 284-6 |
| insulin resistance, 4 | line bisection, 145 | strokes causing amnesia, 278–84 |
| integrative agnosia, 248 | lipid-lowering therapy, 425 | management, 288–9 PCA infarcts and, 36 |
| interleukin, 379 | locked-in syndrome, 317–18, 327, 335 | prognosis and recovery, 288 |
| International Classification of Diseases | associated lesions, 337 management, 337 | short-term memory, 24 spatial memory assessment, 205 |
| and Related Health Problems, | | |
| | | |
| 10th revision (ICD-10), 10, | long-term memory, 297 | working memory, 24 central executive deficits, 303–5 |
| | | working memory, 24 |

| stroke deficits, 303 visual working memory, 301–3 | multi-infarct dementia, 1, 26, 392 history of terminology, 9 | input/output, 102 quantity-processing deficits, 105-6 |
|--|--|---|
| mesiofrontal stroke, 26 | multiple sclerosis, 71 | transcoding, 102 |
| Messerli Test, 258 | musical perception, 119-20 | triple code, 101 see also acalculia |
| metabolic syndrome, 4 | mutism, 23 aphasic, 23 | Nun Study, 2, 3 |
| metacognitive process assessment, 267–8 | see also akinetic mutism | object agnosia, 248-50 |
| microsomatognosia, 172 | myoclonic dystonia, 47 | Object Location Test, 206 |
| midbrain lesions | myoclonus, negative, see asterixis | object recognition |
| alteration of level of consciousness, | n-back test, 303, 307 | non-visual, 251 prosopagnosia relationship, 234–6 |
| 321–3, 327–9 dystonia and, 48 | National Institute of Neurological Disorders and Stroke (NINDS), | see also face recognition; visual agnosia |
| middle cerebral artery (MCA), lesions agraphia association, 92–3 | see NINDS-AIREN; NINDS-CSN | object use, 56 |
| alexia association, 93 | negative autoscopy, 182 | impairment assessment, 59 |
| alteration of level of consciousness, 330 | negative myoclonus, see asterixis | object-centered neglect, 302 |
| delirium and, 345 | neglect | obsessive-compulsive disorder, 38 |
| dysexecutive syndrome, 262-3 | auditory, 120 | obtundation, 315 |
| hemineglect association, 137–8 left, 35 | dissociations between subtypes, 133–4 | occipitotemporal cortex, 103 role in prosopagnosia, 232–3 |
| agraphia association, 93 alexia association, 92–3 | dyslexia, 87 associated lesions, 91 | oculoleptomeningeal amyloidosis, 397 |
| neglect dyslexia association, 91 | functional neurophysiological | optic aphasia, 35, 247, 249 |
| right, 37, 38 middle fusiform gyrus, face | anomalies, 143 motor, 130–1, 145, 173 | optic ataxia, 219–20, 222 assessment, 226 |
| recognition role, 233 | object-centered, 302 | Organic Brain Syndrome Scale, 343 |
| migraine, 71 | personal, 146, 173 representational, 133, 142, 146 | orthography, impaired access to, 87 |
| Mini Mental State Examination | see also hemineglect | from vision, 87 |
| (MMSE), 28, 401, 413 | NEO five-factor inventory, 359 | orthography-to-phonology |
| minimally conscious state, 317, 318 | neuroimaging, see imaging studies | correspondence, impaired |
| mirror asomatognosia, 185 | vascular cognitive impairment diagnosis, 16 | access to, 87–8 combined deficits, 88 |
| misidentification delusion, 352–3 | Neuropsychiatric Inventory, 267, 417 | Ota's task, 144 |
| misoplegia, 178, 179 | neuroticism, 359 | oto-acoustic emissions, 122 |
| mixed transcortical aphasia, 68 | National Institutes of Health stroke | out-of-body experience, 183 |
| molecular biomarkers, 16 | scale, 28 | |
| Montgomery–Asberg Depression Rating Scale, 364 | NINDS-AIREN criteria for vascular | PACE trial, 383 |
| Montreal Cognitive Assessment | dementia, 388–9, 410 | palipsychism, 36 pantomime, 55 |
| (MoCA), 28, 413–14 | NINDS-CSN cognitive test list, 413 | paramedian artery, 263–4, 281–2 |
| Montréal–Toulouse Battery, 65, 71, 241 | harmonization conference, 411 | infarct effects on consciousness, |
| mood disorder with a general medical condition, 354 | initial validation, 418–20 neuropsychological protocols, 413, | 321–3 territory, 321–2 |
| motivational interviewing, 369 | 414, 416 | Patient Competency Rating Scale, 164 |
| motor awareness theory of | non-conscious hemiasomatognosia, 172 | pattern span test, 307 |
| anosognosia, 166 | number processing, 101–2, 104 | PCA, see posterior cerebral artery |
| motor neglect, 130-1, 173 assessment, 145 | anatomical implementation, 102–3 calculation, 102 | peduncular hallucinosis, 121 |
| movement disorders, <i>see</i> abnormal involuntary movement | deficits, 106–8 hemispheric specialization, 103–4 | perceptual extinction, 129–30 anatomical correlates, 141–2 |

Index

| perseverations, 256, 257, 258 | recurrent stroke prevention, 423-4 | quality of life fatigue impact, 381 |
|---|---|---|
| persistent vegetative state, 317, 335 | symptoms, 428 | health-related quality of life, 367 |
| associated lesions, 337 | vascular risk factors, 424-7 | |
| personal neglect, 132, 142, 173 | see also dementia | reading, 86 assessment, 93–4 |
| anosognosia relationship, 164–5 | post-stroke depression determinants, 366 | see also alexia; dyslexia |
| assessment, 146 | • | receptive aprosodia, 358 |
| personality, 356 | post-stroke depression, 36 diagnosis, 363–5 | Recognition Memory Test, 241 |
| personality change, 356–7 | frequency, 366 | reduplicative paramnesia, 25, 37 |
| apathy, 358 assessment, 5, 359 | future directions, 370 impact, 367 | representational neglect, 133 |
| brain damage association, 357 | management, 367–70 | anatomical correlates, 142 |
| emotional incontinence, 358 | electroconvulsive therapy, 370 | assessment, 146 |
| management, 359, 360 post-stroke depression risk | pharmacotherapy, 367-9 psychological therapies, 369-70 | response initiation and suppression |
| relationship, 359 | natural history, 366 | deficits, 257–8 vascular dementia, 398 |
| receptive aprosodia, 358 | routine screening, 365-6 | retrosplenial cortex lesions, memory |
| stroke association, 357–8 violent and aggressive behavior, | see also depression | impairment, 284 |
| 358-9 | prefrontal cortex, working memory and, 300, 303–5 | reverse digit span test, 307 |
| phantom limbs, 173-6 | premotor neglect, 130 | Riddoch's phenomenon, 209–10 |
| supernumerary, 174-6 | presenile dementia with cerebral | right hemisphere syndromes, 34, 36–8 |
| phonemic disarticulation, 35 | hemorrhage, 397 | cognitive syndromes, 36–7 |
| phonemic identification and discrimination, 123 | Present State Examination, 364 | neuropsychiatric syndromes, 38 |
| phonological dyslexia, 88 | pre-stroke dementia, 29 | rule use deficits, 258 |
| phonological loop, 298 | prism adaptation, 148, 185 | screening tests, 28 |
| phonological representations, impaired | problem solving deficits, 258 | semantic memory, 277 |
| access to, 88–9 | problem-solving therapy, 369 | semantic representations, impaired |
| polyopic heautoscopy, 182 | PROFESS trial, 424–5 | access to, 88 combined deficits, 88 |
| pontine lesions, alteration of level of | PROGRESS trial, 402 | senile dementia, 9 |
| consciousness, 327–9 | prosopagnosia, 231 | sequences of auditory signals, 122 |
| post-stroke psychosis, see delusion; | frequency, 232 | serial 7's test, 307 |
| psychosis | lesion localization, 232–3 laterality, 232 | |
| posterior cerebral artery (PCA), lesions alexia association, 91–2 | nature of, 236–40 | short-term memory, 297 impairment, 24 |
| cortical blindness and, 212–13 | neuropsychological assessment, | spatial memory assessment, 205 |
| delirium and, 344 | 240–1 specificity, 233–6 | short-term recall test, 308 |
| left, 35–6 memory impairment, 278–80 | subtypes, 236 | silent infarct, 2 |
| neglect dyslexia association, 91 | pseudobulbar syndrome, 358 | simultanagnosia, 214, 220-1 |
| right, 37 | pseudo-extinction, 146 | assessment, 227 |
| visual agnosia and, 250-1 | pseudo-hemianopia, 128 | Six Elements test, 258 |
| posterior parietal cortex Bálint syndrome lesions, 223–4 | pseudo-sixth phenomenon, 321 | sleep disturbance, 378 |
| posterior reversible encephalopathy, | psychogenic blindness, 213 | small vessel disease, 11 |
| 26-8 | psychosis, 38 | social behavior impairment, 256 |
| post-stroke dementia, 11, 387, 423 | diagnostic criteria, 351 | somatoparaphrenia, 176–80, 353 |
| treatment | pupillary reaction to light, 213 | anatomical findings, 179 varieties of, 177 |
| cognitive decline prevention, 424–6 | pure tone audiometry, 121 | spasm of fixation, 220 |
| dementia progression prevention, | pure word deafness, 114, 117-18, 120 | • |
| 426-7 | subtypes, 118 | spastic dysarthria, 79 |

440

| patial attention disorders Balint syndrome, 220-1 spatial neglect, see hemineglect, neglect speech apraxia of, 35 disturbances, 33 production, 76-7, 81 speech perception tests, 122-3 see also specify conditions speech and language therapy aphasis, 72-3 auditory perception disorders, 123-4 dysarthria, 82 spelling, 86, 89 spellin | spatial acalculia, 104 | superior longitudinal fascicle | transcranial magnetic stimulation, |
|--|---|--|---|
| spatial neglect, see hemineglect; neglect spatial neglect, see hemineglect; neglect, see dyslexia, 87, 88 sustained attention deficit, 259 take coordination deficit, 259 task coordination of level of consciousness, see alteration of neuropsycholal extinction, 172 ascular organitive disorder, 10, 410 ascular organitive impairment, 1, 5, 9, 410 ascular organitive im | = | | aphasia treatment, 73 |
| spech agraxia of, 35 disturbances, 33 production, 76-7, 81 speech perception tests, 122-3 see also specific conditions speech and language therapy aphasia, 72-3 auditory perception disorders, 123-4 dysarthria, 82 spelling, 86, 89 splitting of the body image, 181 star cancellation test, 144 statios, 425 strato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stroke recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hyperholoesterolemia, 423-4 hyperthonocysteinemia, 423-6 dysexecutive syndrome, 266-6 clinical caxamination, 205 subcortical sphasia, 69 surface dyslexia, 87, 88 sustained attention deficit, 259 test for upper limb apraxia, 58 thalamic lesions alketic mutism, 26 alteration of level of consciousness anteromedian, central and posterolateral thalamic infarct, 323-5 rostral mesencephalic 324-5 rostral mesencephalic 324-5 rostral mesencephalic 324-5 rostral mesencephalic 324-5 rostral mesencephalic 441-12 subarachnoid hemory 445-16 sea los vigardina, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical syndrome, 11 subarachnoid hemory 411-12 subarachnoid hemory 412-17 subarachnoid hemory 412-17 subarachnoid hemory 413-16 subcortical sphasia, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical syndrome, 11 subcortical syndrome, 21 subcortical syndrome, 11 subcortical syndrome, 11 subco | | supernumerary phantom limbs, 174–6 | transitivism, 178 |
| specch perception tests, 122–3 see also specific conditions speech and language therapy aphasia, 72–3 task coordination deficit, 258, 259 spaling, 86, 89 sustained attention deficit, 259 test for upper limb apraxia, 58 thalamic lesion, 49–50 truor of consciousness, see alteration of level of consciousness admired preception disorders, 123–4 dysarthria, 82 spelling, 86, 89 sater acancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-rewards association assessment, 267 stress hormones, 341–2 stroke recurrent stroke prevention, 423–4 anithrombotic drugs, 424 diabetes mellitus, 423 hyperchonocysteinemia, 425 see also subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 correlated factors, 382 epidemiology, 382 subcortical sphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 39–401 control of the salar syndrome, 210 co | spatial neglect, see hemineglect; neglect | supplementary motor area lesions, 33 | |
| surface dyslexia, 87, 88 groduction, 76-7, 81 speech perception tests, 122-3 see also specific conditions speech and language therapy aphasia, 72-3 auditory perception disorders, 123-4 dysarthria, 82 spelling, 86, 89 spliting of the body image, 181 star cancellation test, 144 statios, 425 strato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-cretered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stroke recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hyperhonocysteinemia, 423-4 hyperthonocysteinemia, 423-4 hyperthonocysteinemia, 423-4 hyperthonocysteinemia, 423-4 hyperthonocysteinemia, 423-4 hyperthonocysteinemia, 423-4 shypertholoisterolemia, 423-4 hyperthonocysteinemia, 423-4 shypertholoisterolemia, 423-6 dysexcutive syndrome, 266-6 clinical examination, 205 subcortical aphasia, 69 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome and, 264-5 fatigue affer, 382 correlated factors, 382 eridemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome and, 264-5 fatigue affer, 382 correlated factors, 382 eridemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome and, 264-5 fatigue affer, 382 correlated factors, 382 eridemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome and, 264-5 fatigue affer, 382 correlated factors, 382 eridemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome and, 264-5 fatigue affer, 382 correlated factors, 382 eridemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 subarachnoid hemorrhage delirium and, 345-6 dysexcutive syndrome, 205-6 clinical examination, 202-3 clinical examination, 202-3 clinical ex | | surface dysgraphia, 87, 88 | |
| speech perception tests, 122-3 see also specific conditions speech and language therapy aphasia, 72-3 auditory perception disorders, 123-4 dysarthria, 82 spelling, 86, 89 spell | | surface dyslexia, 87, 88 | , |
| speech perception tests, 122–3 see also specific conditions speech and language therapy aphasia, 72–3 test for upper limb apraxia, 58 thalamic lesions auditory perception disorders, 123–4 dysarthria, 82 spelling, 86, 89 spelling of the body image, 181 star cancellation test, 144 stereotypic behavior, 256 statuc-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-crewards association assessment, 267 stress hormones, 341–2 strato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, | · · | sustained attention deficit, 258, 259 | · |
| speech and language therapy aphasia, 72–3 auditory perception disorders, 123–4 dysarthria, 82 spelling, 86, 89 splitting of the body image, 181 state, kinetic dissociation, 210, 214 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hyperhomocysteinemia, 423–4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 Stroke Tests, 815 curved Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical sphasia, 69 subcortical schemic vascular dementia, 2, 11–12, 393, 412 subcortical sphasia, 69 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 subcortical ischemic vascular dementia, 2, 39–340 subcortical syndrome, 11 subcortical ischemic vascular dementia, 1, 9, 387 assessment, 399–401 subcortical syndrome, 1, 9, 387 assessment, 399–401 subcortical syndrome, 11 subcortical ischemic vascular dementia, 1, 9, 387 assessment, 399–401 subcortical syndrome, 11 subcortical ischemic vascular dementia, 1, 9, 387 assessment, 399–401 subcortical syndrome, 12, 12, 239, 412 subcortical syndrome, 12, 12, 239, 41 | | Syst-Eur trial, 402 | • |
| test for upper limb apraxia, 58 auditory perception disorders, 123-4 dysarthria, 82 spelling, 86, 89 splitting of the body image, 181 star cancellation test, 144 statins, 425 star cancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stries hormones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stroke recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423-4 hypertheosion, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 test for upper limb apraxia, 58 thalamic lesions akinetic mutism, 26 alteration of level of consciousness anteromedian, central and posteriolaterial thalamic infarct, 323-7 combined polar and paramedian infarct, 323 paramedian infarcts, 321-3 rostral mesencephalic- hypothalamic-thalamic infarct, 324-4 dyssecutive syndrome, 263-4 dyssecutive syndrome, 263-4 dyssecutive syndrome, 263-4 dyssecutive syndrome, 263-4 dyssecutive syndrome, 271 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prognosis, 206 prognosis, 206 prospoagnosia association, 234 stroke relationships, 203-5 Tower of London, 258 Trail Making Test, 414 part B, 267, 308 transcortical aphasia, 67 sensory aphasia, 68 subcortical syndrome, 11 | • • | took accordination deficit 250 | two-factor theory of anosognosia, 100 |
| auditory perception disorders, 123-4 dysarthria, 82 shelling, 86, 89 sheli | | · | - |
| dysarthria, 82 spelling, 86, 89 spelling, 86, 89 spelling, 86, 89 star cancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 strokeromones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stroker recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423-4 hyperthoolesterolemia, 423-4 hyperthomocysticimenia, 423-4 hyperthodicaterological assessment, 59 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prognosis, 206 prosopagnosia association, 23-4 stroke relationships, 203-5 Tower of London, 258 Trail Making Test, 414 language and visuospatial tests, 415-16 memory domain tests, 414 language and visuospatial tests, 412-17 screening examination, 412-17 screening examination, 412-18 case vignettes, 5, 10, 410-11 molecular biomarkers, 16 engidemiology, 9-10 imaging studies, 4-5 mild impairment, 5 neuropsychological assessment, 205-6 classification, 203 management, 206 prognosis, 206 prosopagnosia association, 23-4 stroke relationships, 203-5 rower of London, 25 | | | |
| alteration of level of consciousness anteromedian, central and posterolateral thalamic infarct, 323-57 combined polar and paramedian infarct, 323 paramedian infarct, 323 paramedian infarct, 321 rostral mesencephalic— hypothalamic-thalamic infarct, 324-5 testo-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stress hormones, 341-2 striato-pallidal lesions, dystonia and, 46-7 stress hormones, 423-4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid demorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical alphasia, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical sphasia, 69 subcortical syndrome, 11 stranscranial direct current stimulation, 11 stranscranial direct current stimulation, 12 season and paramedian infarcts, 321-3 roombined polar and paramedian infarcts, 321-3 roombined polar and paramedian infarcts, 321-3 rostral mesencephalic—hypothalamic-thalamic infarct, 321-3 rostral mesencephalic—hypothalamic-thalamic infarct, 324-4 dystonia and, 47-8 left, 36 memory impairment, 280-2 tremor and, 49-50 vascular dementia and, 391-2 theory of mind, 257 token tests, 415 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prognosis, 206 prognosis association, 234 stroke relationships, 203-5 force of London, 258 troke relationships, 203-5 small vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 non-infarct pathology, 12 treatment, 17-18 see also cognitive impairment of dementia, 2, 11-12, 393, 412 subcortical | | | * * |
| splitting of the body image, 181 star cancellation test, 144 statins, 425 star cancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stato-kinetic dissociation, 210, 214 streotypic behavior, 256 streotypic behavior, 256 streotypic behavior, 256 streotypic behavior, 267 streotypic behavior, 267 streotypic behavior, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423–4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 211 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 210 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 210 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 253–4 token tests, 415 diany function, 417–18 etiologic heterogeneity and, 411–12 language and visuospatial tests, 415–16 memory domain tests, 415 neuropsychological assessment, 410 case vignettes, 13–16 diagnostic criteria, 5, 10, 410–11 molecular biomarkers, 16 neurorimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9–10 imaging studies, 4–5 mild impairment, 5 neuropsychological assessment, 411–12 large vescutive syndrome, 211 subarchnoid hemorrhage delirium and, 391–2 theory of mind, 257 diagnostic cri | · | · · · · · · · · · · · · · · · · · · · | dysaitiiia, 79–80 |
| star cancellation test, 144 statins, 425 star cancellation test, 144 statins, 425 star cancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46-7 stroke recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423-hyperhomocysteinemia, 423-hyperthomocysteinemia, 423-hyperthomocysteinemia, 423-hyperthosion, 232 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 station-kinetic dissociation, 210, 214 stimulus-centered neglect, 87 stimulus-rewards association assessment, 260- tolorium and, 344 dysexecutive syndrome, 263-4 dystonia and, 47-8 left, 36 memory domain tests, 415 neuropsychological assessment, 210-21 scase vignettes, 13-16 diagnostic criteria, 5, 10, 410-11 molecular biomarkers, 16 neuropsychological assessment, 201 sidiagnostic criteria, 5, 10, 410-11 molecular biomarkers, 16 neuropsychological assessment, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prospoagnosia association, 203 management, 206 prospoagnosia association, 204 striate district, 324 str | | | vascular cognitive disorder, 10, 410 |
| star cancellation test, 144 statins, 425 stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hyperhomocysteinemia, 423–4 hypertholoesterolemia, 423 hyperhomocysteinemia, 423–4 hypertholoesterolemia, 423 hyperhomocysteinemia, 423–4 hypertholoesterolemia, 423 hyperthologischial stems, 59 tructured Clinical Interview for DSM-IV, 364 structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical sischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 combined polar and paramedian infarcts, 321–3 rostral mesencephalic- hypothalamic-thalamic infarct, 321–3 todalimicat, 323 aparamedian infarcts, 321–3 rostral mesencephalic- hypothalamic-thalamic infarct, 411–12 executive domain tests, 414 language and visuospatial tests, 415–16 memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 token tests, 415 diagnuage and visuospatial tests, 418–16 memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 token tests, 415 neuropsychological assessment, 91 revaluation, 13 history of terminology, 9- | | | vascular cognitive impairment, 1, 5, 9, |
| stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 streeotypic behavior, 256 streeotypic behavior, 256 streeotypic behavior, 256 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423 hypercholesterolemia, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical sphasia, 69 subcortical sphasia, 69 subcortical syndrome, 11 stranscranial direct current stimulation, strony Test, 267, 307, 417, 412 subcortical syndrome, 11 statio, 210, 214 paramedian infarcts, 321–3 rostral mesencephalic-hypothalamic-thalamic infarct, 321 hypothalamic-thalamic infarct, 424 dysexecutive syndrome, 263–4 dystonia and, 47–8 memory domain tests, 415 etiologic heterogeneity and, 411–12 executive domain tests, 415 nemory domain tests, 415 neas visuorspsychological assessment, 29 top of the basilar syndrome, 211, 320–1 topographical disorientation, 202–3 assessment, 205–6 classification, 5, 201 topographical disorientation, 202–3 assessment, 205–6 classification, 5, 201 clinical presentation, 4, 12–18 case vignettes, 13–16 nemory domain tests, 415 neuropsychological assessment, 201 clinical presentation, 202–3 assessment, 205–6 impairment assessment, 205 neuropsychological assessment, 205 neuropsychological assessment, 205 neuropsychological assessment, 205 neuropsychological assessment, 206 neuropsychological assessment, 205 n | star cancellation test, 144 | | |
| stato-kinetic dissociation, 210, 214 stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hyperhomocysteinemia, 423–4 hypertension, 423 hyperhomocysteinemia, 423–4 hypertension, 423 ssee also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 263–4 dystonia and, 47–8 left, 36 memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 theory of mind, 257 token tests, 415 tolo use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320–1 topographical disorientation, 202–3 assessment, 205–6 classification, 203 management, 206 prognosis, 206 prognosis, 206 delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical alphasia, 69 subcortical jahasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 parall minatics, 232–3 hypotholalmic-thalamic infarct, dystorial mesencephalic hypothalamic-thalamic infarct, 324–5 delirium and, 344 dysexecutive syndrome, 263–4 dystonia and, 47–8 left, 36 memory impairment, 280–2 tremor and, 49–50 theory of mind, 257 token tests, 415 tolo use, 56 impairment assessment, 59 diagnostic criteria, 5, 10, 410–11 molecular biomarkers, 16 neuroimaging role, 16 executive domain tests, 414 language and visuospatial tests, 415–16 memory domain tests, 415 neuropsychological assessment, 12–17 screening examinations, 413–14 classification, 5, 410 classification, 5, 410 classification, 20–3 diagnostic criteria, 5, 10, 410–11 molecular biomarkers, 16 neuroimaging role, 16 predimicology, 11 evaluation, 13 history of terminology, 9–10 imaging studies, 4–5 mild impairment, 28 mall vessel disease, 11 subcortical ischemic v | statins, 425 | infarct, 323 | |
| stereotypic behavior, 256 stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423 hypercholesterolemia, 423 hypercholesterolemia, 423 hypercholesterolemia, 423 hyperthonide hemorrhage: specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome, 210 token tests, 415 token tests, 415 tolo use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320–1 sases also subarachnoid hemorrhage: specific lesions Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical alphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 transcranial direct current stimulation, syndrome, 263–4 dystonia and, 47–8 left, 36 memory impairment, 280–2 tremor and, 49–50 memory impairment, 280–2 tremor and, 49–50 tremor and, 391–2 theory of mind, 257 token tests, 415 token tests, 41 | stato-kinetic dissociation, 210, 214 | | daily function, 417-18 |
| stimulus-centered neglect, 87 stimulus-rewards association assessment, 267 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423–4 hyperthonocysteinemia, 423–4 hyperthomocysteinemia, 423–4 hyperthomocysteinemia, 423–4 hyperthomocysteinemia, 423–4 hyperthomocysteinemia, 423–4 hyperthomocysteinemia, 423–4 hypertholesterolemia, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 344 dysexecutive syndrome, 263–4 dystonia and, 47–8 left, 36 memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 theory of mind, 257 token tests, 415 diagnosis, 5, 410 clinical presentation, 5, 410 clinical presentation, 4, 12–18 case vignettes, 13–16 diagnosis, 5 diagnosis criteria, 5, 10, 410–11 molecular biomarkers, 16 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9–10 imaging studies, 4–5 mild impairment, 5 neuropsychological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia, (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 | stereotypic behavior, 256 | | |
| stimulus-rewards association assessment, 267 dystonia and, 47-8 left, 36 memory impairment, 280-2 tremor and, 49-50 vascular dementia, 2,11-12, 393, 412 subcortical ischemic vascular dementia, 2,11-12, 393, 412 stransparsal in transcratial plassia, 35 subcortical ischemic vascular dementia, 2,11-12, 393, 412 stransparsal in transcratial in transcranial direct current stimulation, 415-14 diapstess assessment, 415-16 memory domain tests, 415 neuropsychological assessment, 412-17 sememory domain tests, 415-16 neuropsychological assessment, 412-17 sexentine memory domain tests, 415-16 neuropsychological assessment, 412-17 sexentine per per portine diasorite and tool use, 56 diagnosis, 5 diagnosis, 5 diagnosis, 5 diagnosis, 5 diagnosis | stimulus-centered neglect, 87 | | |
| dystonia and, 47–8 left, 36 stress hormones, 341–2 striato-pallidal lesions, dystonia and, 46–7 stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423–4 hypertension, 423 hyperthomocysteinemia, 423–4 hypertension, 423 hyperthomocysteinemia, 423–4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 dystonia and, 47–8 left, 36 memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 theory of mind, 257 token tests, 415 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320–1 topographical disorientation, 202–3 assessment, 205–6 classification, 203 management, 206 prognosis, 206 prospagnosia association, 234 stroke relationships, 203–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 Trail Making Test, 414 Part B, 267, 308 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 dystonia memory impairment, 280–2 tremor and, 49–50 vascular dementia and, 391–2 token tests, 415 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320–1 topographical disorientation, 202–3 assessment, 205–6 classification, 203 management, 206 prognosis, 206 pr | | The state of the s | |
| striato-pallidal lesions, dystonia and, 46-7 stroke recurrent stroke prevention, 423-4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423-4 hyperthomocysteinemia, 423-4 hyperthomocystein | | dystonia and, 47–8 | |
| striato-pallidal lesions, dystonia and, 46–7 tremor and, 49–50 vascular dementia and, 391–2 tremor and, 49–50 vascular dementia and, 391–2 tremor and, 49–50 vascular dementia and, 391–2 theory of mind, 257 theory of mind, 257 token tests, 415 token tests, 415 token tests, 415 tol use, 56 impairment assessment, 59 hypercholesterolemia, 423 hypercholesterolemia, 423-4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical aphasia, 69 subcortical syndrome, 11 subcortical dementia, 11, 9, 387 assessment, 205–6 classification, 391–2 stremor and, 49–50 vascular dementia and, 391–2 stremor and, 49–50 token tests, 415 classification, 5, 410 clinical presentation, 4, 12–18 case vignettes, 13–16 diagnosis, 5 diagnostic criteria, 5, 10, 410–11 molecular biomarkers, 16 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9–10 imaging studies, 4–5 mild impairment, 5 neuropathological subtypes, 11–13, male and valuation, 205 neuropathological subtypes, 11–13, subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia, 1, 9, 387 subcortical syndrome, 211 subcortical syndrome, 211 subcortical syndrome, 211 subcortical ischemic vascular dementia, 1, 9, 387 subcortical syndrome, 211, 200–1 see also cognitive impairment, 11 subcortical syndrome, 211 subcortical syndrome, 2 | stress hormones, 341–2 | | |
| stroke stroke recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423–4 hyperthomocysteinemia, 423–6 clinical sexemination, 202–3 assessment, 205–6 classification, 204 history of terminology, 9–10 imaging studies, 4–5 mild impairment, 5 neuropathological subtypes, 11–13, subcortical gischemic vascular dementia, 11–12 treatment, 17–18 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment, no dementia, 1, 9, 387 subcortical syndrome, 11 transc | | | 412–17 |
| recurrent stroke prevention, 423–4 antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423–4 hyperthomocysteinemia, 423–5 idiagnostic criteria, 5, 10, 410–11 molecular biomackers, 16 neuroimaging studies, 4–5 mild impairment, 5 neuropathological subtypes, 11–13, subcortical ischemic vas | | | |
| antithrombotic drugs, 424 diabetes mellitus, 423 hypercholesterolemia, 423 hypercholesterolemia, 423 hyperthomocysteinemia, 423-4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 token tests, 415 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 classification, 203 management, 206 prognosis, 206 prographical disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prognosis, 206 neuroix disorientation, 202-3 assessment, 205-6 classification, 203 management, 206 prospagnosia association, 234 stroke relationships, 203-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 Trail Making Test, 414 Part B, 267, 308 transcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 transcranial direct current stimulation, transcranial direct current stimulation, tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 classification, 203 nanagement, 206 prognosia, 206 prospagnosia association, 234 stroke relationships, 203-5 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular dementia, 1, 9, 387 assessment, 390-401 transcranial direct current stimulation, transcranial direct current stimulation, tool use, 56 impair ment assessment, 59 indiagnostic criteria, 5, 10, 410-11 molecular biomarkers, 16 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of | | theory of mind, 257 | |
| hypercholesterolemia, 423 hyperhomocysteinemia, 423-4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical sphasia, 69 subcortical syndrome, 11 tool use, 56 impairment assessment, 59 top of the basilar syndrome, 211, 320-1 top of the basilar syndrome, 210-1 top of the basilar syndrome, 210-1 top of the basilar syndrome, 2 | | token tests, 415 | case vignettes, 13–16 |
| hypercholesterolemia, 423 hyperhomocysteinemia, 423-4 hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical syndrome, 211, 320-1 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 classification, 203 management, 206 prognosis, 206 prosopagnosia association, 234 stroke relationships, 203-5 Tower of London, 258 transcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 impairment assessment, 59 molecular biomarkers, 16 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9-10 imaging studies, 4-5 mild impairment, 5 neuropathological subtypes, 11-13, 411-12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 211, 320-1 impairment assessment, 59 molecular biomarkers, 16 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9-10 imaging studies, 4-5 mild impairment, 5 neuropathological subtypes, 11-13, 411-12 large vessel disease, 11 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, | · · · · · · · · · · · · · · · · · · · | tool use, 56 | |
| hypertension, 423 see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 top of the basilar syndrome, 211, 320-1 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 classification, 203 management, 206 prognosis, 206 prosopagnosia association, 234 stroke relationships, 203-5 Tower of London, 258 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 top of the basilar syndrome, 211, 320-1 specific lesions topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 classification, 203 neuroimaging role, 16 epidemiology, 11 evaluation, 13 history of terminology, 9-10 imaging studies, 4-5 mild impairment, 5 neuropathological subtypes, 11-13, 411-12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, | | | |
| see also subarachnoid hemorrhage; specific lesions Stroop Test, 267, 307, 414, 418 Structured Clinical Interview for DSM-IV, 364 subarachnoid hemorrhage delirium and, 345-6 dysexecutive syndrome and, 264-5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical syndrome, 11 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 neuropsychological assessment, 205-6 mild impairment, 5 neuropathological subtypes, 11-13, 411-12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular dementia, 2, 11-12, 393, 412 subcortical syndrome, 11 topographical disorientation, 202-3 assessment, 205-6 clinical examination, 205 mild imaging studies, 4-5 mild impairment, 5 neuropathological subtypes, 11-13, 411-12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11-12 treatment, 17-18 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399-401 | | top of the basilar syndrome, 211, 320-1 | |
| structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 sussessment, 205–6 clinical examination, 205 neuropsychological assessment, 205–6 classification, 203 management, 206 prognosis, 206 prosopagnosia association, 234 stroke relationships, 203–5 Tower of London, 258 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 suscortical syndrome, 11 suscortical examination, 205 mild impairment, 5 neuropathological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 suscortical syndrome, 11 transcranial direct current stimulation, assessment, 399–401 | ** | - · · | epidemiology, 11 |
| Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 stroop 1est, 267, 307, 414, 418 neuropsychological assessment, 206 neuropathological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, 200 to 10 subcortical syndrome, 11 child impairment, 5 neuropathological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 assessment, 399–401 | hemorrhage; specific lesions | | |
| Structured Clinical Interview for DSM-IV, 364 stupor, 317 subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical schemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 sutiopsychological assessment, 392 classification, 203 management, 206 prosopagnosia association, 234 stroke relationships, 203–5 relatiopsychological assessment, 5 neuropathological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia, 2, 11–12, 393, 412 sensory aphasia, 68 vascular dementia, 1, 9, 387 subcortical syndrome, 11 relatiopsychological assessment, 5 neuropathological subtypes, 11–13, 411–12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, | Stroop Test, 267, 307, 414, 418 | | |
| stupor, 317 subarachnoid hemorrhage delirium and, 345–6 yrosopagnosia association, 203 stroke relationships, 203–5 subcortical aphasia, 69 transcortical aphasia, 69 transcortical syndrome, 11 classification, 203 handle relationships, 203 anneuropathological subtypes, 11–13, 411–12 large vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular dementia, 2, 11–12, 393, 412 sensory aphasia, 68 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399–401 | Structured Clinical Interview for | | |
| subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subarachnoid hemorrhage prognosis, 206 prosopagnosia association, 234 stroke relationships, 203–5 subcortical, 258 dementia, 11–12 treatment, 17–18 see also cognitive impairment see also cognitive impairment vascular cognitive impairment, no dementia, 2, 11–12, 393, 412 sensory aphasia, 68 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, subcortical syndrome, 11 management, 206 prognosis, 206 prosopagnosia association, 234 small vessel disease, 11 non-infarct pathology, 12 small vessel disease, 11 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 assessment, 399–401 | DSM-IV, 364 | | |
| subarachnoid hemorrhage delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 prosopagnosia association, 234 stroke relationships, 203–5 stroke relationships, 203–5 stroke relationships, 203–5 stroke relationships, 203–5 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia, 2, 11–12, 393, 412 sensory aphasia, 67 vascular dementia, 1, 9, 387 subcortical syndrome, 11 rower of London, 258 dementia, 11–12 treatment, 17–18 see also cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 subcortical syndrome, 11 ranscranial direct current stimulation, | stupor, 317 | | |
| delirium and, 345–6 dysexecutive syndrome and, 264–5 fatigue after, 382 correlated factors, 382 epidemiology, 382 subcortical aphasia, 69 subcortical ischemic vascular franscortical aphasia, 35 subcortical syndrome, 11 prosopagniosa association, 254 stroke relationships, 203–5 subcortical ischemic vascular dementia, 11–12 treatment, 17–18 see also cognitive impairment vascular cognitive impairment, no dementia, 2, 11–12, 393, 412 sensory aphasia, 67 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399–401 | | | |
| fatigue after, 382 | | | small vessel disease, 11 |
| correlated factors, 382 epidemiology, 382 Trail Making Test, 414 Part B, 267, 308 subcortical aphasia, 69 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 Trail Making Test, 414 Part B, 267, 308 see also cognitive impairment vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 assessment, 399–401 assessment, 399–401 | | • | _ |
| epidemiology, 382 Part B, 267, 308 see also cognitive impairment subcortical aphasia, 69 transcortical aphasia, 35 subcortical ischemic vascular dementia, 2, 11–12, 393, 412 subcortical syndrome, 11 motor aphasia, 67 sensory aphasia, 68 vascular cognitive impairment, no dementia (VCI-ND), 9, 410 vascular dementia, 1, 9, 387 assessment, 399–401 assessment, 399–401 | | · | - |
| subcortical ischemic vascular motor aphasia, 67 dementia, 2, 11–12, 393, 412 sensory aphasia, 68 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399–401 | epidemiology, 382 | | |
| subcortical ischemic vascular motor aphasia, 67 dementia (VCI-ND), 9, 410 dementia, 2, 11–12, 393, 412 sensory aphasia, 68 vascular dementia, 1, 9, 387 subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399–401 | subcortical aphasia, 69 | | |
| subcortical syndrome, 11 transcranial direct current stimulation, assessment, 399-401 | | motor aphasia, 67 | dementia (VCI-ND), 9, 410 |
| transcrama direct current dimination, | | · - | |
| | subcortical syndrome, 11 | transcranial direct current stimulation, 308 | assessment, 399–401 cerebrovascular disease, 399–401 |



Index

vascular dementia (cont.) markers, 401 neuropsychological assessment, 401 Binswanger disease, 392-3 CADASIL, 393-6, 400-1 categories of, 390-1 causes, 390 rare causes, 396-7 diagnostic criteria, 387-90 hemodynamic mechanisms, 398 multi-infarct dementia, 392 multiple brain hemorrhages and amyloid angiopathies, 397-8 neuropsychology of, 398-9 prevalence, 1 single stroke dementia, 391-2 cortical stroke, 391 subcortical stroke, 391-2 subcortical ischemic, 2 treatment, 402-3, 427-8 blood pressure reduction, 402 pharmacotherapy, 402-3 see also dementia vascular depression, 366-7, 416 vascular generalized chorea, 52 vascular parkinsonism, 50-2 diagnostic criteria, 50 pathophysiology, 52 ventral attention network, 302 ventral intermediate nucleus lesions, 47 - 8tremor and, 49-50 vestibular caloric stimulation, see caloric vestibular stimulation violent behavior, 358-9

visual acuity measurement, 214 visual agnosia, 247 assessment, 251-3 color perception and categorization, 252 copying and drawing from memory, 251-2 error analysis, 251 matching tests, 252 non-visual object recognition, 251 causes, 250 strokes, 250-1 management, 253 prognosis, 253 standardized testing, 252-3 visual attention deficit assessment, 226 - 7visual cueing paradigm, 146 visual disturbances, 24, 39 see also cortical blindness; specific conditions visual evoked potentials and cortical blindness, 215 visual feedback, 185 visual field assessment, 214 visual grasp reflex, 220 Visual Object and Space Perception Battery, 240, 252 visuoconstructive disorders, 193-6 assessment, 199 causative strokes, 199 in stroke, 198-9 frequency, 198 prognosis, 199-200

visuospatial sketchpad, 298 dorsal, 302-3 ventral, 301-2 Wallenberg syndrome, 81, 318 Wechsler Adult Intelligence Scale, Wechsler Memory Scale, 240, 241 Wernicke aphasia, 35, 67-8 Wernicke area, working memory and, 300-1 Western Aphasia Battery, 65, 416 Wisconsin Card Sorting Test, 258, 267, 414, 418 word discrimination test, 121 word span test, 307 working memory, 297-8 capacity, 305-7 cognitive models, 298-9 impairment, 24 central executive deficits, 303-5 cognitive rehabilitation, 308 dysexecutive syndrome, 259 phonological deficits, 300-1 stroke deficits, 303 visual working memory, neuroscientific studies, 299-300 tests of, 306, 307-8 writing, 86 assessment, 93-4 see also agraphia xenomelia, 178